Global Generic Oncology Drugs Market Size By Product Type (Large Molecule Drugs, Small Molecule Drugs), By Application (Hospital Pharmacies, Retail Pharmacies), By Geographic Scope And Forecast

Generic Oncology Drugs Market Size And Forecast

Generic Oncology Drugs Market size was valued at USD 28,525.04 Million in 2024 and is projected to reach USD 44,269.36 Million by 2031, growing at a CAGR of 6.23% from 2024 to 2031.

The Global Generic Oncology Drugs Market has witnessed strong growth owing to the escalating prevalence of cancer disease coupled with advantages offered by generic medicines. With the rapid increase in the number of sedentary lifestyles, colorectal, and extreme exposure to ultraviolet rays, the number of cancer cases has undergone a notable rise across the globe. The Global Generic Oncology Drugs Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Generic Oncology Drugs Market Definition

Generic Oncology Drugs are the subsequent breed of cancer medicines that comes with an affordable price shift and quality faith. Generic Drugs are essential in oncology because fewer anticancer drugs are only available as generics. Generic drugs are cost-effective as the manufacturers have not spent in the development and marketing of the new drug. When a drug patent terminates, other manufacturers apply for FDA approval to manufacture and sell the product. Hence generic drugs are more affordable than branded drugs. Generic Oncology Drugs have turned into an effective treatment option for symbolic cancer cases, the manufacturers on the other end are concentrating on introducing a new product with a quality difference over the present product.

Global Generic Oncology Drugs Market Overview

The Global Generic Oncology Drugs Market is principally driven by the escalating prevalence of cancer disease coupled with advantages offered by generic medicines. With the rapid increase in the number of sedentary lifestyles, colorectal, and extreme exposure to ultraviolet rays, the number of cancer cases has undergone a notable rise across the globe. Generic drugs are widely used in supportive care. The most meaningful benefit of using generic drugs is the cost, which is up to 85% less than that of branded drugs. Thus, these benefits given by generic drugs are expected to intensify the market growth during the forecast period. Furthermore, expansion of generics at a mass scale, expanding exports by Indian manufacturers, new trade agreements by Asian companies with international players for sales, distribution as well as research collaborations as well as the launch of innovative and novel generics for cancer treatment are other factors driving the market growth. The increased government expenditure in the healthcare industry is anticipated to be a key trend propelling the growth of the industry.

On the other hand, concerns amongst oncologists regarding the effectiveness & bioequivalence of generic drugs will produce a bar for the market growth. Besides, consumption of a significant amount of time for drug approval may hinder Generic Oncology Drugs Market growth in the coming years. Nevertheless, the increasing importance of the research and development of drugs and therapies for cancers such as lung, multiple myeloma, colorectal, and prostate, is anticipated to create tremendous growth opportunities for the market. Rising awareness about the advantages of early cancer diagnosis and growing inclination toward precautionary measures are also contributing to the market opportunities.

Global Generic Oncology Drugs Market Segmentation Analysis

The Global Generic Oncology Drugs Market is segmented based on Product Type, Application, And Geography.

Generic Oncology Drugs Market, By Product Type

• Large Molecule Drugs
• Small Molecule Drugs

Based on Product Type, The market is segmented into large molecule drugs, and small molecule drugs. The Small Molecule Drugs segment is estimated to witness the highest CAGR for the forecast period. The growth of the segment is attributed to benefits of small molecules in terms of their complexity and molecular size that can cross during reach the target site and show their powerful action as well as the advent of personalized drug development. One of the key advantages of small molecules is that these drugs have low molecular weight and simple chemical structures. The aforementioned pros of large molecule drugs are expected to rise consumer preference in the market segment resulting in better market revenue in the forecasted period.

Generic Oncology Drugs Market, By Application

• Hospitals
• Retails
• Other

Based on Application, The market is segmented into hospitals, retails, and Other. Hospitals segments is the largest contributor to global oncology drugs market. Increased number of oncology research and development activities coupled with number of hospitals across the globe is expected to drive the market segment. For an instance, according to Centers for Medicare & Medicaid Services, the total number of hospitals in 2018 was around 9,31,555 which increased to 9,32,559 in 2019. The above data depicts the higher number of hospitals in the regions which will ultimately increases the demand for oncology drugs in the forecasted period.

Generic Oncology Drugs Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

The Global Generic Oncology Drugs Market is segmented on the basis of geography into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America accounted for the largest revenue share in 2021 and is expected to maintain its dominance during the research period owing to presence of large patient population, strong presence of key players, easy availability of drugs, well-developed healthcare infrastructure, favorable healthcare reimbursement policies, higher number of research, development and innovation activities and higher adoption of modern therapies. However, Asia Pacific is expected to grow at the highest CAGR due to the increase in the number of cancers affected population and increasing awareness about various cancers. Increasing incidence of cancer diseases is one of the important drivers of the Generic Oncology Drugs Market. As more individuals are diagnosed with cancer diseases, they look for more medicines for the treatment.

Key Players

The “Global Generic Oncology Drugs Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Aurobindo Pharma, Celgene, GlaxoSmithKline, Hikma Pharmaceuticals, Merck, Mylan, Natco Pharma, Novartis, Pfizer, Teva Pharmaceutical, Bayer AG, and others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis.

Key Developments

• In June 2021, Bayer AG has acquired two companies named PSMA Therapeutics Inc., Noria Therapeutics Inc. The aquisition is expected is expected to drive the market capture for bayers across the globe.

• In April 2021, Sanofi has acquired a biotech company called Tidal Therapeutics. The acquisition will help Sanofi to research and develop ,RNA based oncology drugs to pacify the market demand in the future.

• July 2021 – AstraZeneca has received approval for oncology drugs from National Medical Products Administration of China. The approval will enable the company to market their product across the China region.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the global Generic Oncology Drugs Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.

Porter’s Five Forces

The image provided would further help to get information about Porter’s five forces framework providing a blueprint for understanding the behavior of competitors and a player’s strategic positioning in the respective industry. The porter’s five forces model can be used to assess the competitive landscape in global Generic Oncology Drugs Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

Report Scope

Research Methodology of Market Research